Hansa Biopharma AB (HNSA) Price & Analysis

Compare

1 Followers

HNSA Stock Chart & Stats

Day’s Range― - ―

52-Week Rangekr19.58 - kr57.30

Previous CloseN/A

Volume97.73K

Average Volume (3M)462.19K

Market Cap

kr2.60B

Enterprise Valuekr2.41B

Total Cash (Recent Filing)kr354.42M

Total Debt (Recent Filing)kr906.21M

Price to Earnings (P/E)―

Beta0.10

Next Earnings

Oct 23, 2025

EPS Estimate

-1.41

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.53

Shares Outstanding84,763,220

10 Day Avg. Volume658,362

30 Day Avg. Volume462,187

Financial Highlights & Ratios

PEG Ratio0.16

Price to Book (P/B)-4.18

Price to Sales (P/S)14.38

P/FCF Ratio-3.65

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

kr143.00

Price Target Upside370.39% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Debt ManagementThe company renegotiated its debt with Novaquest, converting a large portion of it into equity and pushing out cash payments to June 2027.

Market ExpansionMuch stronger commercial adoption of Idefirix in the US is expected than what has been seen in Europe.

Reimbursement ExpansionHansa secured reimbursement for Idefirix in both Australia and Switzerland.

Bears Say

Financial ConcernsThe company has capital needs that exceed current cash balance.

Regulatory ChallengesImlifidase only has conditional approval in the EU and no US approval.

Sales ImpactGermany's decision to pull out from the Eurotransplant desensitization program is expected to impact near-term sales of Idefirix.

Hansa Biopharma AB News

Hansa Biopharma Announces Extraordinary General Meeting for Board Elections

The latest update is out from Hansa Biopharma AB ( ($SE:HNSA) ). Hansa Biopharma AB has announced an...

2d ago

Hansa Biopharma AB: Promising Growth in Gene Therapy with Imlifidase Breakthrough

Hansa Biopharma AB, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Douglas Tsao...

5d ago

Hansa Biopharma Reports Positive Trial Results for Imlifidase in DMD Gene Therapy

Hansa Biopharma AB ( ($SE:HNSA) ) just unveiled an update. Hansa Biopharma has announced promising results from a...

7d ago

Hansa Biopharma Strengthens Leadership Team with Key Appointments

The latest update is out from Hansa Biopharma AB ( ($SE:HNSA) ). Hansa Biopharma announced key executive appointments...

10d ago

Hansa Biopharma’s Phase 3 Trial: A Potential Breakthrough in Kidney Transplantation

Hansa Biopharma (($SE:HNSA)) announced an update on their ongoing clinical study. Hansa Biopharma’s recent clinical study, officially titled...

21d ago

HNSA

Hansa Biopharma AB: Buy Rating Affirmed Amidst Growth Potential and Strategic Financial Moves

Analyst Douglas Tsao from H.C. Wainwright maintained a Buy rating on Hansa Biopharma AB and keeping the price...

22d ago

Hansa Biopharma’s Earnings Call Highlights Growth and Stability

Hansa Biopharma (($SE:HNSA)) has held its Q2 earnings call. Read on for the main highlights of the call....

22d ago

Hansa Biopharma Strengthens Financial Position and Leadership Amidst Strong Sales Growth

Hansa Biopharma AB ( ($SE:HNSA) ) has provided an announcement. Hansa Biopharma announced a successful capital raise of...

23d ago

Hansa Biopharma’s Phase 3 Study on Imlifidase: A Potential Game Changer in Kidney Transplantation

Hansa Biopharma (($SE:HNSA)) announced an update on their ongoing clinical study. Hansa Biopharma’s recent clinical study, titled ‘An...

23d ago

HNSA

Hansa Biopharma Appoints New Chief Medical Officer

Hansa Biopharma AB ( ($SE:HNSA) ) has shared an update. Hansa Biopharma has appointed Dr. Richard Philipson as...

1M ago

HNSA FAQ

What was Hansa Biopharma AB’s price range in the past 12 months?

Hansa Biopharma AB lowest stock price was kr19.58 and its highest was kr57.30 in the past 12 months.

What is Hansa Biopharma AB’s market cap?

Hansa Biopharma AB’s market cap is kr2.60B.

When is Hansa Biopharma AB’s upcoming earnings report date?

Hansa Biopharma AB’s upcoming earnings report date is Oct 23, 2025 which is in 75 days.

How were Hansa Biopharma AB’s earnings last quarter?

Hansa Biopharma AB released its earnings results on Jul 17, 2025. The company reported -kr2.53 earnings per share for the quarter, missing the consensus estimate of -kr1.66 by -kr0.87.

Is Hansa Biopharma AB overvalued?

According to Wall Street analysts Hansa Biopharma AB’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Hansa Biopharma AB pay dividends?

Hansa Biopharma AB does not currently pay dividends.

What is Hansa Biopharma AB’s EPS estimate?

Hansa Biopharma AB’s EPS estimate is -1.41.

How many shares outstanding does Hansa Biopharma AB have?

Hansa Biopharma AB has 84,763,220 shares outstanding.

What happened to Hansa Biopharma AB’s price movement after its last earnings report?

Hansa Biopharma AB reported an EPS of -kr2.53 in its last earnings report, missing expectations of -kr1.66. Following the earnings report the stock price went up 7.556%.

Which hedge fund is a major shareholder of Hansa Biopharma AB?

Currently, no hedge funds are holding shares in SE:HNSA

Company Description

Hansa Biopharma AB

Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

Hansa Biopharma AB (HNSA) Earnings & Revenues

Historic Earnings Reports

HNSA Stock 12 Month Forecast

Average Price Target

kr143.00

▲(370.39% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"kr21","144":"kr144","51.75":"kr51.8","82.5":"kr82.5","113.25":"kr113.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":143,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr143.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":143,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr143.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":143,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr143.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,51.75,82.5,113.25,144],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Dec<br/>2024","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.48,37.28923076923077,46.098461538461535,54.90769230769231,63.71692307692308,72.52615384615385,81.33538461538461,90.14461538461539,98.95384615384616,107.76307692307692,116.57230769230769,125.38153846153847,134.19076923076923,{"y":143,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.48,37.28923076923077,46.098461538461535,54.90769230769231,63.71692307692308,72.52615384615385,81.33538461538461,90.14461538461539,98.95384615384616,107.76307692307692,116.57230769230769,125.38153846153847,134.19076923076923,{"y":143,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.48,37.28923076923077,46.098461538461535,54.90769230769231,63.71692307692308,72.52615384615385,81.33538461538461,90.14461538461539,98.95384615384616,107.76307692307692,116.57230769230769,125.38153846153847,134.19076923076923,{"y":143,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":34,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.1,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.64,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.95,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.56,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.52,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.46,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.58,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.72,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.12,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.28,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.48,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >